Pharmacy Pearls: Aspirin for ASCVD

October 17th, 2022 | Pharmacy Pearls•Cardiology

In this edition of Pharmacy Pearls, you will find updated guidance released by the US Preventive Services Task Force and reviewed by local cardiologists about when to use and when to stop aspirin for Atherosclerotic Cardiovascular Disease (ASCVD) prevention in primary care. Included is an algorithm that providers can use to determine when aspirin therapy is appropriate, and when it might be appropriate to discontinue aspirin use based on a patient’s ASCVD risk and bleeding risk. As always, we welcome any questions or feedback you may have. Just email the Pharmacy Team.

Taking too long?

Reload document

Open in new tab

Download PDF [293.25 KB]

135 Corporate Woods, Suite 320
Rochester, New York 14623-1466

Phone: (585) 758-7823
Fax: (585) 424-1268

Website by:

This is not an offer to purchase or a solicitation of an offer to purchase any securities or interest in Accountable Health Partners, LLC (AHP). An offer will only be made by means of a confidential private placement memorandum and subscription agreement.

ABI Value	Interpretation	Recommendation
Greater than 1.4	Calcification/vessel hardening	Refer to vascular specialist
1.0 - 1.4	Normal	None
0.9 - 1.0	Acceptable	None
0.8 - 0.9	Some arterial disease	Treat risk factor
0.5 - 0.8	Moderate arterial disease	Refer to vascular specialist
Less than 0.5	Severe arterial disease	Refer to vascular specialist

Pharmacy Pearls: Aspirin for ASCVD

Pharmacy Pearls: Aspirin for ASCVD

GENERAL COVID-19 INFORMATION